Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease
出版年份 2014 全文链接
标题
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 2, Pages 219-227
出版商
Informa Healthcare
发表日期
2014-09-17
DOI
10.1517/13543784.2015.963195
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
- (2014) Marcelo Lima et al. CNS & Neurological Disorders-Drug Targets
- Molecular Effects of L-dopa Therapy in Parkinson’s Disease
- (2014) Jolanta Dorszewska et al. CURRENT GENOMICS
- Levodopa-related cysteinyl–glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients
- (2014) Thomas Müller et al. JOURNAL OF NEURAL TRANSMISSION
- Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates
- (2014) Christine Swanson et al. NEUROLOGICAL RESEARCH
- Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
- (2013) Matteo Monami et al. ACTA DIABETOLOGICA
- Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights
- (2013) Carlos Vallarino et al. CLINICAL DRUG INVESTIGATION
- Methyl Group–Donating Vitamins Elevate 3-O-Methyldopa in Patients With Parkinson Disease
- (2013) Thomas Müller et al. CLINICAL NEUROPHARMACOLOGY
- PPAR-γ: Therapeutic Prospects in Parkinson's Disease
- (2013) Anna R. Carta CURRENT DRUG TARGETS
- Pioglitazone and Cancer: Angel or Demon?
- (2013) Michael Kostapanos et al. CURRENT PHARMACEUTICAL DESIGN
- Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
- (2013) M. Ferwana et al. DIABETIC MEDICINE
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
- (2013) CHIN-HSIAO TSENG et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- Sleep and non-motor symptoms in Parkinson’s disease
- (2013) Antonia Maass et al. JOURNAL OF NEURAL TRANSMISSION
- Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
- (2013) Bradley F Boeve LANCET NEUROLOGY
- Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
- (2013) C. Bosetti et al. ONCOLOGIST
- Shared dysregulated pathways lead to Parkinson's disease and diabetes
- (2013) Jose A. Santiago et al. TRENDS IN MOLECULAR MEDICINE
- Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γAgonist against MPTP
- (2013) Christine R. Swanson et al. PPAR Research
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Pioglitazone and bladder cancer: a propensity score matched cohort study
- (2012) Li Wei et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
- (2012) I. N. Colmers et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis
- (2012) Zhaowei Zhu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
- (2012) A. Neumann et al. DIABETOLOGIA
- Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study
- (2012) Ronac Mamtani et al. JNCI-Journal of the National Cancer Institute
- Clinical features of Parkinson disease when onset of diabetes came first: A case-control study
- (2012) E. Cereda et al. NEUROLOGY
- Association Between Pioglitazone and Urothelial Bladder Cancer
- (2012) Yanina Barbalat et al. UROLOGY
- The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
- (2012) L. Azoulay et al. BMJ-British Medical Journal
- PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation
- (2011) Tamas Varga et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
- (2011) Joo-Ho Shin et al. CELL
- Pioglitazone and Bladder Cancer: A population-based study of Taiwanese
- (2011) C.-H. Tseng DIABETES CARE
- Diabetes and Risk of Parkinson's Disease
- (2011) Q. Xu et al. DIABETES CARE
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
- (2011) Christine R Swanson et al. Journal of Neuroinflammation
- Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients
- (2011) Thomas Müller et al. MOVEMENT DISORDERS
- Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
- (2011) Kurt A. Jellinger MOVEMENT DISORDERS
- The controversy of levodopa toxicity in Parkinson disease
- (2011) Theresa A. Zesiewicz Nature Reviews Neurology
- Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model
- (2011) A.R. Carta et al. NEUROSCIENCE
- PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
- (2010) B. Zheng et al. Science Translational Medicine
- Unbalanced M1/M2 Phenotype of Peripheral Blood Monocytes in Obese Diabetic Patients: Effect of pioglitazone
- (2009) N. Satoh et al. DIABETES CARE
- PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease
- (2009) Nicoletta Schintu et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
- (2009) Shugo Suzuki et al. TOXICOLOGICAL SCIENCES
- Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease
- (2008) Pramod Kumar et al. BEHAVIOURAL BRAIN RESEARCH
- Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)
- (2008) S. E. Kahn et al. DIABETES CARE
- Expression of Peroxisome Proliferator-Activated Receptor-γ in Key Neuronal Subsets Regulating Glucose Metabolism and Energy Homeostasis
- (2008) David A. Sarruf et al. ENDOCRINOLOGY
- PPAR: a therapeutic target in Parkinsons disease
- (2008) Rajnish K. Chaturvedi et al. JOURNAL OF NEUROCHEMISTRY
- Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor Agonist
- (2008) N. Nicolakakis et al. JOURNAL OF NEUROSCIENCE
- The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
- (2008) Anthony H.V. Schapira MOVEMENT DISORDERS
- Regulation of Glial Cell Functions by PPAR- Natural and Synthetic Agonists
- (2008) Antonietta Bernardo et al. PPAR Research
- Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
- (2007) Ramya Kapadia Frontiers in Bioscience-Landmark
- Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague–Dawley rats
- (2007) Randy L. Hunter et al. NEUROSCIENCE LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search